Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) were severe, progressive diseases that impaired physical functioning, with the 6-minute walk test (6MWT) ...
The EMA approved Adempas four months after Opsumit but for two indications- PAH and chronic thrombo-embolic pulmonary hypertension (CTEPH). However, the EMA estimated only a minor increase in the ...
Methods All patients with idiopathic or heritable PAH diagnosed in 1995–2008 were identified. Controls were selected from patients with chronic thromboembolic pulmonary hypertension (CTEPH). Full ...
In order to obtain a wide range of perspectives on living with PH, we aimed to include patients with PAH or CTEPH of varying severities, from several different countries and with a wide range of ...